Catalyst Event
Biogen Inc (BIIB) · Other
From Akros U.S. Tech 100 Protective Allocation Monthly Index (A100PAM)
5/24/2026, 12:00:00 AM
U.S. FDA decision on the supplemental application for LEQEMBI IQLIK on 2026-05-24; price impact is estimated to be ≥10% as a major drug catalyst, expected.
Korean Translation
미국 FDA의 2026년 5월 24일 레켐비 이클릭 피하주사 제형 승인 결정; 주요 신약 촉매제로서 10% 이상의 주가 영향이 예상됨.
Related Recent Events
Cloudflare Inc (NET) · Other
Cloudflare is scheduled to host an Investor Day on June 9, 2026; a >=5% price impact is estimated as the company provides strategic updates scheduled.
6/9/2026, 12:00:00 AM
Medtronic PLC (MDT) · Earnings Release
Medtronic will report its financial results for the fourth quarter and full fiscal year 2026 on June 3, 2026 (High importance estimated due to potential volatility from annual results), scheduled.
6/3/2026, 12:00:00 AM
Hewlett Packard Enterprise Co (HPE) · Earnings Release
Q2 2026 earnings release is scheduled.
6/2/2026, 12:00:00 AM
Marvell Technology Inc (MRVL) · Earnings Release
First quarter fiscal year 2027 earnings results are scheduled to be released on May 29, 2026. Market impact is estimated at >1% as earnings releases typically drive volatility scheduled.
5/29/2026, 12:00:00 AM
Analog Devices Inc (ADI) · Earnings Release
Analog Devices is expected to release its fiscal second quarter 2026 financial results around late May. The date is estimated based on previous reporting schedules and is scheduled.
5/28/2026, 12:00:00 AM
Axon Enterprise Inc (AXON) · Other
Axon's Annual Meeting of Shareholders on 2026-05-28 where director Matthew McBrady will not seek re-election, which is estimated to have low importance as board changes are common, is scheduled.
5/28/2026, 12:00:00 AM